Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Merle Foster who wrote (23020)	10/24/2000 12:49:30 PM
From: Brander	Respond to of 23519

Sorry, but no I don't. I really had not been paying much attention to ACTIS until Patscara brought it up. Maybe he can answer your good question?

To: Sidney Merle Foster who wrote (23020)	10/26/2000 11:57:10 AM
From: Brander	Read Replies (1) \| Respond to of 23519

Here is some Vivus news: biz.yahoo.com Thursday October 26, 10:04 am Eastern Time Press Release VIVUS Opens Patient Enrollment for Its Female Sexual Dysfunction Clinical Study MOUNTAIN VIEW, Calif.--(BW HealthWire)--October 26, 2000--VIVUS, Inc. (Nasdaq NM: VVUS - news) today announced that they have begun patient enrollment in the clinical program for the Company's female sexual dysfunction (FSD) product, ALISTA(TM). It is estimated that over 40% of women report some form of FSD, including both organic and psychogenic causes. Researchers have classified the range of symptoms seen in FSD into four subcategories: desire, arousal, orgasmic and sexual pain disorders. The VIVUS clinical program is designed to evaluate ALISTA in women with a primary complaint of sexual arousal disorder, or FSAD. ``This is an exciting time for VIVUS as we expand our clinical development program to include products to help women improve their quality of life,'' said Leland F. Wilson, President and CEO. ``Results from this initial clinical study of ALISTA will aid in the design of larger studies that are required for the global regulatory approval process.'' ALISTA is a proprietary formulation of alprostadil applied locally to the female genitalia. Alprostadil is a synthetic version of a naturally occurring vasodilating agent found in the body. It is the same active ingredient found in VIVUS' product, MUSE®, used to treat male erectile dysfunction. ALISTA is believed to increase blood flow to the female genitalia, thereby promoting engorgement and other natural processes that occur during sexual stimulation. With both issued and pending patents, the Company believes it has the dominant patent position for the local delivery of prostaglandins, such as alprostadil, in the treatment of women with FSD. Local administration has the potential to deliver high concentrations of active agent to the site of action while reducing exposure to the rest of the body, thereby limiting potential side effects. VIVUS, Inc. is a specialty pharmaceutical company engaged in the development of innovative therapies for quality-of-life disorders in men and women, with a focus on sexual dysfunction. The Company developed and markets in the U.S. the product MUSE® (alprostadil) and the medical device ACTIS®, two innovations in the treatment of erectile dysfunction (ED). VIVUS has partnered with Abbott Laboratories (NYSE: ABT - news) for the international marketing and distribution of its male ED products. The Company also has ongoing R&D programs in premature ejaculation and future-generation ED products. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). This news release contains forward-looking statements that involve risks and uncertainties regarding VIVUS Inc.'s operations and future results. Please see the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's Form 10-Ks and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.